FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085383807> ?p ?o ?g. }

• W2085383807 endingPage "436" @default.
• W2085383807 startingPage "435" @default.
• W2085383807 abstract "European Journal of NeurologyVolume 15, Issue 5 p. 435-436 Creutzfeldt-Jakob disease: hopes for therapy M. Pocchiari, M. Pocchiari Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, ItalySearch for more papers by this authorA. Ladogana, A. Ladogana Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, ItalySearch for more papers by this authorS. Graziano, S. Graziano Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, ItalySearch for more papers by this authorM. Puopolo, M. Puopolo Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, ItalySearch for more papers by this author M. Pocchiari, M. Pocchiari Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, ItalySearch for more papers by this authorA. Ladogana, A. Ladogana Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, ItalySearch for more papers by this authorS. Graziano, S. Graziano Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, ItalySearch for more papers by this authorM. Puopolo, M. Puopolo Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, ItalySearch for more papers by this author First published: 03 April 2008 https://doi.org/10.1111/j.1468-1331.2008.02109.xCitations: 6Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Al-Shahi R, Will RG, Warlow CP. Amount of research interest in rare and common neurological conditions: bibliometric study. BMJ 2001; 323: 1461– 1462. 2 Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006; 129: 2241– 2265. 3 Brown P. Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 2002; 58: 1720– 1725. 4 Ladogana A, Casaccia P, Ingrosso L, et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. Journal of General Virology 1992; 73: 661– 665. 5 Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, Race R, Iwaki T. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. Journal of Virology 2004; 78: 4999– 5006. 6 Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulfate in human prion diseases: an observational study in the UK. European Journal of Neurology 2008; 15: 458– 464. 7 Parry A, Baker I, Stacey R, Wimalaratna S. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. Journal of Neurology, Neurosurgery and Psychiatry 2007; 78: 733– 734. 8 Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-Ura K. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opinion of Biological Therapy 2007; 7: 713– 726. 9 Pocchiari M, Puopolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004; 127: 2348– 2359. 10 MRC Clinical Trial Unit. Prion-1 Trial: Quinacrine for human prion disease. A partially randomised patient preference trial to evaluate the activity and safety of quinacrine in human prion disease. Available at http://www.ctu.mrc.ac.uk/studies/cjd.asp (accessed 28/01/2008). 11 Kovács GG, Puopolo M, Ladogana A, et al. Genetic prion disease: the EUROCJD experience. Human Genetics 2005; 118: 166– 174. 12 Kocisko DA, Caughey B, Morrey JD, Race RE. Enhanced antiscrapie effect using combination drug treatment. Antimicrobial Agents and Chemotherapy 2006; 50: 3447– 3449. 13 Kocisko DA, Caughey B. Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo. Journal of Virology 2006; 80: 1044– 1046. Citing Literature Volume15, Issue5May 2008Pages 435-436 ReferencesRelatedInformation" @default.
• W2085383807 created "2016-06-24" @default.
• W2085383807 creator A5006734763 @default.
• W2085383807 creator A5036511534 @default.
• W2085383807 creator A5047695219 @default.
• W2085383807 creator A5064760676 @default.
• W2085383807 date "2008-05-01" @default.
• W2085383807 modified "2023-09-24" @default.
• W2085383807 title "Creutzfeldt-Jakob disease: hopes for therapy" @default.
• W2085383807 cites W1966902515 @default.
• W2085383807 cites W1979080638 @default.
• W2085383807 cites W2019890167 @default.
• W2085383807 cites W2036615200 @default.
• W2085383807 cites W2038096175 @default.
• W2085383807 cites W2082998566 @default.
• W2085383807 cites W2105391259 @default.
• W2085383807 cites W2128494706 @default.
• W2085383807 cites W2136442838 @default.
• W2085383807 cites W2147959459 @default.
• W2085383807 cites W2151541409 @default.
• W2085383807 cites W2166032837 @default.
• W2085383807 doi "https://doi.org/10.1111/j.1468-1331.2008.02109.x" @default.
• W2085383807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18394045" @default.
• W2085383807 hasPublicationYear "2008" @default.
• W2085383807 type Work @default.
• W2085383807 sameAs 2085383807 @default.
• W2085383807 citedByCount "12" @default.
• W2085383807 countsByYear W20853838072012 @default.
• W2085383807 countsByYear W20853838072014 @default.
• W2085383807 countsByYear W20853838072016 @default.
• W2085383807 crossrefType "journal-article" @default.
• W2085383807 hasAuthorship W2085383807A5006734763 @default.
• W2085383807 hasAuthorship W2085383807A5036511534 @default.
• W2085383807 hasAuthorship W2085383807A5047695219 @default.
• W2085383807 hasAuthorship W2085383807A5064760676 @default.
• W2085383807 hasConcept C161191863 @default.
• W2085383807 hasConcept C41008148 @default.
• W2085383807 hasConcept C71924100 @default.
• W2085383807 hasConceptScore W2085383807C161191863 @default.
• W2085383807 hasConceptScore W2085383807C41008148 @default.
• W2085383807 hasConceptScore W2085383807C71924100 @default.
• W2085383807 hasIssue "5" @default.
• W2085383807 hasLocation W20853838071 @default.
• W2085383807 hasLocation W20853838072 @default.
• W2085383807 hasOpenAccess W2085383807 @default.
• W2085383807 hasPrimaryLocation W20853838071 @default.
• W2085383807 hasRelatedWork W1506200166 @default.
• W2085383807 hasRelatedWork W1995515455 @default.
• W2085383807 hasRelatedWork W2039318446 @default.
• W2085383807 hasRelatedWork W2048182022 @default.
• W2085383807 hasRelatedWork W2080531066 @default.
• W2085383807 hasRelatedWork W2748952813 @default.
• W2085383807 hasRelatedWork W2899084033 @default.
• W2085383807 hasRelatedWork W3031052312 @default.
• W2085383807 hasRelatedWork W3032375762 @default.
• W2085383807 hasRelatedWork W3108674512 @default.
• W2085383807 hasVolume "15" @default.
• W2085383807 isParatext "false" @default.
• W2085383807 isRetracted "false" @default.
• W2085383807 magId "2085383807" @default.
• W2085383807 workType "article" @default.